Ionis Pharmaceuticals Stock Forecast, Price & News

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IONS shares have increased by 20.5% and is now trading at $59.19.
View which stocks have been most impacted by COVID-19.

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View analyst ratings for Ionis Pharmaceuticals or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Ionis Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ionis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Ionis Pharmaceuticals.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its earnings results on Wednesday, November, 4th. The company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.11. The firm had revenue of $160 million for the quarter, compared to the consensus estimate of $182.14 million. Ionis Pharmaceuticals had a trailing twelve-month return on equity of 6.57% and a net margin of 7.82%. The business's revenue was down 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.18 earnings per share.
View Ionis Pharmaceuticals' earnings history.

14 brokers have issued 12-month price objectives for Ionis Pharmaceuticals' shares. Their forecasts range from $34.00 to $91.00. On average, they expect Ionis Pharmaceuticals' stock price to reach $64.91 in the next twelve months. This suggests a possible upside of 9.7% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Novavax (NVAX) and United Therapeutics (UTHR).
View all of IONS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Pinnacle Associates Ltd. (0.40%), Sicart Associates LLC (0.29%), Candriam Luxembourg S.C.A. (0.18%), Peregrine Capital Management LLC (0.13%), BLB&B Advisors LLC (0.11%) and Nisa Investment Advisors LLC (0.03%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., BLB&B Advisors LLC, Sicart Associates LLC, Candriam Luxembourg S.C.A., XTX Markets LLC, Sowell Financial Services LLC, Janney Montgomery Scott LLC, and Arden Trust Co. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals or view top insider-selling stocks.

IONS stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, DNB Asset Management AS, Exchange Traded Concepts LLC, Strs Ohio, Pacer Advisors Inc., Peregrine Capital Management LLC, IBM Retirement Fund, and CWM LLC.
View insider buying and selling activity for Ionis Pharmaceuticals or or view top insider-buying stocks.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $59.19.

Ionis Pharmaceuticals has a market capitalization of $8.28 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis. Ionis Pharmaceuticals employs 817 workers across the globe.

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200 or via email at [email protected]